CAJ | 학술논문

目的：评价前列康片对Ⅲ型前列腺炎的临床疗效。方法105例Ⅲ型前列腺炎患者口服前列康片每次2 g，tid，服用6周，治疗前和治疗6周后进行慢性前列腺炎症状指数（NIH-CPSI）评分并复查前列腺液（EPS）血常规。结果治疗6周后，总有效率为84.3％；NIH-CPSI评分及EPS白细胞数目较治疗前均显著下降（ P＜0.05）。结论前列康片治疗Ⅲ型前列腺炎疗效确切。
목적：평개전렬강편대Ⅲ형전렬선염적림상료효。방법105례Ⅲ형전렬선염환자구복전렬강편매차2 g，tid，복용6주，치료전화치료6주후진행만성전렬선염증상지수（NIH-CPSI）평분병복사전렬선액（EPS）혈상규。결과치료6주후，총유효솔위84.3％；NIH-CPSI평분급EPS백세포수목교치료전균현저하강（ P＜0.05）。결론전렬강편치료Ⅲ형전렬선염료효학절。
Objective To evaluate the clinical efficacy of Qianliekang tablets on typeⅢprostatitis.Methods A total of 105 patients with typeⅢprostatitis were enrolled in this study.All patients took 2 g Qianliekang tablets each time for 6 weeks, three times a day.With National Instituted of Health -chronic prostatitis symptom index ( NIH-CPSI ) scores and expressed prostatic secretious ( EPS ) as evaluating indexes , they were compared before and after treatment.Results The total effective rate of Qianliekang tablets was 84.3%after six weeks of treatment.There were sig-nificant statistical differences in NIH-CPSI scores and the amount of leuko-cyte in EPS between before treatment and six weeks after treatment ( P<0.05).Conclusion The results of this study have demonstrated that Qian-liekang tablets has a definite clinical effect on treating type Ⅲprostatitis.